Leonard Gomella, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Lantheus
    Mitigation strategy:
    Peer review
    Date reviewed:
    08/25/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Exelixis
    Mitigation strategy:
    Peer review
    Date reviewed:
    08/25/2022
  • Attribution:
    Self
    Type of financial relationship:
    Intellectual Property Interest (Oncology)
    Ineligible company:
    Thomas Jefferson University
    Mitigation strategy:
    Peer review
    Date reviewed:
    08/25/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Astra Zeneca
    Mitigation strategy:
    Peer review
    Date reviewed:
    08/25/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Specialty Not Specified)
    Ineligible company:
    Merck Pharmaceuticals
    Mitigation strategy:
    Peer review
    Date reviewed:
    08/25/2022
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Specialty Not Specified)
    Ineligible company:
    MDx Health
    Mitigation strategy:
    Peer review
    Date reviewed:
    08/25/2022
  • Attribution:
    Self
    Type of financial relationship:
    Health Publishing (Specialty Not Specified)
    Ineligible company:
    Wolters Kluwer
    Mitigation strategy:
    Peer review
    Date reviewed:
    08/25/2022
  • Attribution:
    Self
    Type of financial relationship:
    Health Publishing (Specialty Not Specified)
    Ineligible company:
    Canadian Journal of Urology
    Mitigation strategy:
    Peer review
    Date reviewed:
    08/25/2022
  • Attribution:
    Self
    Type of financial relationship:
    Health Publishing (Specialty Not Specified)
    Ineligible company:
    Merck Manual
    Mitigation strategy:
    Peer review
    Date reviewed:
    08/25/2022
  • Attribution:
    Self
    Type of financial relationship:
    Health Publishing (Specialty Not Specified)
    Ineligible company:
    McGraw Hill
    Mitigation strategy:
    Peer review
    Date reviewed:
    08/25/2022
Return to The Evolving Landscape of Advanced Prostate Cancer Treatment: A Guidelines and Case-Based Discussion: A Virtual Course (2022)